SCHEMBL5134752

SCHEMBL5134752

CCCCN(Cc1c(F)cccc1Cl)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.39
TSHR P16473 3/20 0.39
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 3/20 0.36
HPGD P15428 3/20 0.36
HSD17B10 Q99714 3/20 0.36
CYP3A4 P08684 2/20 0.36
CRHR1 P34998 2/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
LMNA P02545 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
BCL2L1 Q07817 1/20 0.35
BAK1 Q16611 1/20 0.35
GAA P10253 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
P2RX7 Q99572 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136139 0.97 TSHR (0.37) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL5137176 0.96 C5AR1 (0.37) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL5072419 0.96 CRHR1 (0.36) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL5134964 0.93 P2RX7 (0.40) ALDH1A1CRHR1POLBMAPTLMNA
SCHEMBL5134866 0.93 TSHR (0.42) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL5074878 0.93 TSHR (0.42) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL5136067 0.92 KDM4E (0.41) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL5135045 0.92 C5AR1 (0.38) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL5136698 0.90 ALDH1A1 (0.39) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL5134701 0.90 KDM4E (0.39) C5AR1TSHRALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed